Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Crossref DOI link: https://doi.org/10.1177/1352458517727603
Published Online: 2017-09-05
Published Print: 2018-10
Update policy: https://doi.org/10.1177/sage-journals-update-policy
Giovannoni, Gavin
Soelberg Sorensen, Per
Cook, Stuart
Rammohan, Kottil
Rieckmann, Peter
Comi, Giancarlo
Dangond, Fernando
Adeniji, Abidemi K
Vermersch, Patrick
Funding for this research was provided by:
EMD Serono Inc.
Merck KGaA
Text and Data Mining valid from 2017-09-05